American Century Companies Inc. Lowers Position in Insulet Co. (NASDAQ:PODD)

American Century Companies Inc. decreased its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 0.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 854,872 shares of the medical instruments supplier's stock after selling 3,597 shares during the period. American Century Companies Inc. owned approximately 1.22% of Insulet worth $223,181,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in PODD. Baillie Gifford & Co. boosted its position in shares of Insulet by 3.5% during the fourth quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier's stock valued at $614,998,000 after buying an additional 79,982 shares during the last quarter. Geode Capital Management LLC lifted its stake in Insulet by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier's stock valued at $403,339,000 after acquiring an additional 22,850 shares in the last quarter. Westfield Capital Management Co. LP lifted its stake in Insulet by 27.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier's stock valued at $175,697,000 after acquiring an additional 163,388 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Insulet by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 646,959 shares of the medical instruments supplier's stock worth $168,902,000 after acquiring an additional 10,694 shares during the last quarter. Finally, Fisher Asset Management LLC grew its stake in shares of Insulet by 7.6% in the 4th quarter. Fisher Asset Management LLC now owns 377,694 shares of the medical instruments supplier's stock worth $98,605,000 after acquiring an additional 26,594 shares in the last quarter.

Remove Ads

Insulet Stock Performance

PODD traded down $1.22 on Tuesday, hitting $272.82. The company's stock had a trading volume of 577,074 shares, compared to its average volume of 690,203. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46. The firm has a market cap of $19.16 billion, a P/E ratio of 47.12, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company's 50 day simple moving average is $272.16 and its 200-day simple moving average is $257.78.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. The firm had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. Analysts forecast that Insulet Co. will post 3.92 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on PODD. Stifel Nicolaus boosted their price target on shares of Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a report on Friday, February 21st. TD Cowen boosted their target price on Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a research note on Friday, January 3rd. Piper Sandler increased their price target on Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. StockNews.com cut Insulet from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. Finally, Canaccord Genuity Group raised their target price on Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $292.06.

Insiders Place Their Bets

In other news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares of the company's stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.47% of the stock is owned by corporate insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.